Filed Nov. 12, 2026

Serial No. 50215169

Class Synthetic peptides for pharmaceutical purposes; Synthetic peptides for the treatment of obesity, type 2 diabetes, and metabolic diseases and disorders; Peptides for the treatment of obesity, type 2 diabetes, and metabolic diseases and disorders; Pharmaceutical preparations for weight loss and weight management; Pharmaceutical preparations for the treatment of obesity and type 2 diabetes; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations, namely, appetite suppressants; Therapeutic agents for weight control and appetite suppression; Medical preparations for slimming purposes; Pharmaceutical preparations in the form of tablets, capsules, and sublingual drops for the treatment of obesity; Dietary and nutritional supplements used for weight loss; Weight management supplements; Dietary and nutritional supplements; Nutraceuticals for use as a dietary supplement; Amino acid preparations for medical purposes; Lipotropic factor preparations; Dietary and nutritional supplements containing semaglutide, tirzepatide, sermorelin, NAD+, BPC-157, TB-500, MOTS-c, and glutathione; 005; 006; 018; 044; 046; 051; 052

Case Type Trademark